An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer (Q40956750)

25 September 2017

title

An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer (English)

1 reference

evasion of host immune response

25 September 2017

main subject

1 reference

Shuichi Takano

1

1 reference

25 September 2017

Hiroaki Saito

series ordinal

2

1 reference

25 September 2017

Masahide Ikeguchi

series ordinal

3

1 reference

25 September 2017

language of work or name

1 reference

22 January 2016

1 reference

25 September 2017

1 reference

25 September 2017

volume

46

1 reference

25 September 2017

issue

11

1 reference

25 September 2017

page(s)

1341-1347

1 reference

Global cancer statistics, 2002

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

21 January 2018

The B7 family revisited

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Clinical relevance of the number of interleukin-17-producing CD 8+ T cells in patients with gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Japanese Classification of Gastric Carcinoma - 2nd English Edition -

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Dysregulated T cell expression of TIM3 in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Interleukin-10 expression significantly correlates with minor CD8+ T-cell infiltration and high microvessel density in patients with gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-016-1305-9

HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26801344

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26801344

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Serum interleukin-6 and -10 levels in patients with gastric cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26801344

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00595-016-1305-9

1 reference

25 September 2017

1 reference